> The pharmaceutical industry's PAC money continues to favor Obama over McCain, with the Democratic candidate now counting about twice as much money from pharma PACs as McCain is. Report
> Brazil's health minister says the country will produce an inexpensive generic version of Stocrin, an AIDS drug made by Merck. Report
> The FDA's new consumer campaign about DTC ads was designed by a non-profit run by an advertising consultant to the pharmaceutical industry. Report
> Karo Bio is testing a novel cholesterol-lowering medicine that may make the Swedish biotechnology company attractive to product-hungry drugmakers Pfizer and AstraZeneca. Report
> Lupin announced that it has acquired a majority stake in South African generics maker Pharma Dynamics. Report
> Valeant Pharmaceuticals said it will buy privately held Coria Laboratories Ltd. for $95 million in a move to expand its dermatology business. Report
> Dr. Reddys launched its U.S. specialty business, Promius Pharma, a wholly owned subsidiary that initially will focus on the branded dermatology market. Report
> Nanotech company Fluidigm is now going public. The South San Francisco based company plans to begin offering 5,300,000 shares at $14 to $16 on Thursday, according to the company's SEC filings. If all goes according to plan, the IPO could raise as much as $85 million. Report
> A new report from MassBIO and the Massachusetts Life Sciences Center finds that the state needs to cultivate more biotech talent if it wants to keep its edge in the industry. Report
> As part of a cost-cutting plan that will save $11 million to $15 million a year, Millipore is closing a plant in Lincoln Park, NJ and another in Nodinge, Sweden. The plant closures will be accompanied by 140 job cuts, and Millipore said it may close two more plants in the UK. Report
And Finally... When vaccine expert Paul Offit released his new book defending vaccines against the attacks of critics claiming a link to autism, he had a new security system installed at his house. Report